Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. (26th June 2014)

• Record Type: Journal Article
• Authors: Scott, Bradley J.; Klein, Agnes V.; Wang, Jian; Korth‐Bradley, Joan; Mager, Donald; Meibohm, Bernd; Zhou, Hong Hui
• Is Part Of: Journal of clinical pharmacology. Volume 55:Number 3(2015:Mar.)
• Page Start: S123
• Page End: S132
• Publication Date: 2014-06-26
• Subjects: Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.339
• Languages: English
• ISSNs: 0091-2700

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jcph339-sec-0001" sec-type="section"> <p>Monoclonal antibodies have become mainstays of treatment for many diseases. After more than a decade on the Canadian market, a number of authorized monoclonal antibody products are facing patent expiry. Given their success, most notably in the areas of oncology and autoimmune disease, pharmaceutical and biotechnology companies are eager to produce their own biosimilar versions and have begun manufacturing and testing for a variety of monoclonal antibody products. In October of 2013, the first biosimilar monoclonal antibody products were approved by the European Medicines Agency (Remsima™ and Inflectra™). These products were authorized by Health Canada shortly after; however, while the EMA allowed for extrapolation to all of the indications held by the reference product, Health Canada limited extrapolation to a subset of the indications held by the reference product, Remicade®. The purpose of this review is to discuss the Canadian regulatory framework for the authorization of biosimilar mAbs with specific discussion around the clinical requirements for establishing (bio)‐similarity and to present the principles that are used in the clinical assessment of <italic>New Drug Submissions</italic> for intended biosimilar monoclonal antibodies. Health Canada's current views regarding indication extrapolation, product interchangeability, and post‐market surveillance are discussed as well.</p> </sec> </abstract>